Cited by 656

The DOI matches its Crossref record; 260 of the 260 references it cites were found in a registry or an index.

Non‐small cell lung cancer in China

Open access

Chen, Peixin, Liu, Yunhuan, Wen, Yaokai, Zhou, Caicun·2022·Cancer Communications

Open this paper in CoChat — free account

Abstract

In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early‐stage non‐small cell lung cancer (NSCLC) patients miss the optimal timing for treatment due to the lack of clinical presentations. Population‐based nationwide screening programs are of significant help in increasing the early detection and survival rates of NSCLC in China. The understanding of molecular carcinogenesis and the identification of oncogenic drivers dramatically facilitate the development of targeted therapy for NSCLC, thus prolonging survival in patients with positive drivers. In the exploration of immune escape mechanisms, programmed cell death protein 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitor monotherapy and PD‐1/PD‐L1 inhibitor plus chemotherapy have become a standard of care for advanced NSCLC in China. In the Chinese Society of Clinical Oncology's guidelines for NSCLC, maintenance immunotherapy is recommended for locally advanced NSCLC after chemoradiotherapy. Adjuvant immunotherapy and neoadjuvant chemoimmunotherapy will be approved for resectable NSCLC. In this review, we summarized recent advances in NSCLC in China in terms of epidemiology, biology, molecular pathology, pathogenesis, screening, diagnosis, targeted therapy, and immunotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/cac2.12359

Cites

260 of 260 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Items 201–260 of 260

The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma
Betz, B. L., Dixon, C. A., Weigelin, H. C., Knoepp, S. M., & Roh, M. H. (2013) · Cancer Cytopathology · doi:10.1002/cncy.21286 · Cited by 68
A manifold learning regularization approach to enhance 3D CT image-based lung nodule classification
Ren, Y., Tsai, M.-Y., Chen, L., Wang, J., Li, S., Liu, Y., Jia, X., & Shen, C. (2019) · International Journal of Computer Assisted Radiology and Surgery · doi:10.1007/s11548-019-02097-8 · Cited by 67
Self-citation
The mortality of lung cancer attributable to smoking among adults in China and the United States during 1990–2017
Liu, X., Yu, Y., Wang, M.-S., Mubarik, S., Wang, F., Wang, Y., Meng, R., & Yu, C. (2020) · 癌症：英文版 · doi:10.1002/cac2.12099 · Cited by 66
Clinical Significance of Folate Receptor-positive Circulating Tumor Cells Detected by Ligand-targeted Polymerase Chain Reaction in Lung Cancer
Wang, L., Wu, C., Qiao, L., Yu, W., Guo, Q., Zhao, M., Yang, G., Zhao, H., & Lou, J. (2016) · Journal of Cancer · doi:10.7150/jca.16856 · Cited by 65
Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project
Finn, S. P., Addeo, A., Dafni, U. G., Thunnissen, E., Bubendorf, L., Madsen, L. B., Biernat, W., Verbeken, E. K., Hernández‐Losa, J., Marchetti, A., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.02.016 · Cited by 64
Indoor Air Pollution Increases the Risk of Lung Cancer
Chen, K.-C., Tsai, S., Shie, R., Zeng, C., & Yang, H. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19031164 · Cited by 63
Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer
Pan, Y., Zheng, D., Li, Y., Cai, X., Zheng, Z., Jin, Y., Hu, H., Cheng, C., Shen, L., Wang, J., et al. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.08.61 · Cited by 62
EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer
Lü, S., Yu, Y., Li, Z., Yu, R., Wu, X., Bao, H., Ding, Y., Shao, Y. W., & Jian, H. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.006 · Cited by 62
KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples
Loong, H. H.-F., Du, N., Cheng, C., Lin, H., Guo, J., Lin, G., Li, M., Jiang, T., Shi, Z., Cui, Y., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-455 · Cited by 62
Single nucleotide polymorphisms in DNA repair genes and putative cancer risk
Köberle, B., Koch, B., Fischer, B., & Hartwig, A. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1771-2 · Cited by 61
Kurtosis and skewness assessments of solid lung nodule density histograms: differentiating malignant from benign nodules on CT
Kamiya, A., Murayama, S., Kamiya, H., Yamashiro, T., Oshiro, Y., & Tanaka, N. (2013) · Japanese Journal of Radiology · doi:10.1007/s11604-013-0264-y · Cited by 60
The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population
Skov, B. G., Rørvig, S. B., Jensen, T., & Skov, T. (2019) · Modern Pathology · doi:10.1038/s41379-019-0339-0 · Cited by 60
KIF5B‐RET fusions in Chinese patients with non–small cell lung cancer
Cai, W., Su, C., Li, X., Fan, L., Zheng, L.-M., Fei, K., & Zhou, C. (2013) · Cancer · doi:10.1002/cncr.27940 · Cited by 58
Self-citation
Cisplatin versus Carboplatin-Based Regimens for the Treatment of Patients with Metastatic Lung Cancer. An Analysis of Veterans Health Administration Data
Santana-Dávila, R., Szabó, A., Arce-Lara, C. E., Williams, C. D., Kelley, M. J., & Whittle, J. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000146 · Cited by 58
[China National Lung Cancer Screening Guideline with Low-dose Computed Tomography (2023 Version)].
(2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.102.10 · Cited by 58
Multi-Level Cross Residual Network for Lung Nodule Classification
Lyu, J., Bi, X., & Ling, S. H. (2020) · Sensors · doi:10.3390/s20102837 · Cited by 57
Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving Immunotherapy
Trebeschi, S., Bodalal, Z., Boellaard, T. N., Bucho, T. M. T., Drago, S. G., Kurilova, I., Calin-Vainak, A. M., Pizzi, A. D., Muller, M., Hummelink, K., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.609054 · Cited by 57
Association between Chronic Obstructive Pulmonary Disease and Lung Cancer: A Case-Control Study in Southern Chinese and a Meta-Analysis
Wang, H., Yang, L., Zou, L., Huang, D., Guo, Y. L., Pan, M., Tan, Y., Zhong, H., Ji, W., Ran, P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046144 · Cited by 53
Stressful social relations and mortality: a prospective cohort study
Lund, R., Christensen, U., Nilsson, C. J., Kriegbaum, M., & Rod, N. H. (2014) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2013-203675 · Cited by 53
Radiation exposure and lung disease in today's nuclear world
Deas, S. D., Huprikar, N., & Skabelund, A. J. (2016) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000349 · Cited by 49
Pleural Plaques and the Risk of Lung Cancer in Asbestos-exposed Subjects
Brims, F., Kong, K., Harris, E. J. A., Sodhi‐Berry, N., Reid, A., Murray, C. P. J., Franklin, P., Musk, A. W., & de Klerk, N. H. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201901-0096oc · Cited by 48
Ten-Year Trends of Clinicopathologic Features and Surgical Treatment of Lung Cancer in China
Zang, R., Shi, J., Lerut, A., Wang, L., Liu, C., Brunelli, A., Petersen, R. H., Ng, C. S. H., Lim, E. K. S., & Gao, S. (2019) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2019.08.017 · Cited by 47
The Regimen of Computed Tomography Screening for Lung Cancer: Lessons Learned Over 25 Years From the International Early Lung Cancer Action Program
Henschke, C. I., Yip, R., Shaham, D., Zulueta, J. J., Aguayo, S. M., Reeves, A. P., Jirapatnakul, A. C., Avila, R. S., Moghanaki, D. M., & Yankelevitz, D. F. (2020) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000538 · Cited by 46
Ceritinib: a Review in ALK-Positive Advanced NSCLC
Deeks, E. D. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0460-7 · Cited by 40
Real‐world EGFR testing in patients with stage IIIB/IV non‐small‐cell lung cancer in North China: A multicenter, non‐interventional study
Cheng, Y., Wang, Y., Zhao, J., Liu, Y., Gao, H., Ma, K., Zhang, S., Xin, H., Liu, J., Han, C., et al. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12859 · Cited by 37
Self-citation
Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study
Xu, L., Qian, Q., Zhang, Y., Cui, J., Liu, R., & Li, Y. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.008 · Cited by 37
Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non–Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab
Augustyn, A., Adams, D. L., He, J., Qiao, Y., Verma, V., Liao, Z. X., Tang, C., Heymach, J. V., Tsao, A. S., & Lin, S. H. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.06.016 · Cited by 37
Lung Cancer Occurrence—Correlation with Serum Chromium Levels and Genotypes
Baszuk, P., Janasik, B., Pietrzak, S., Marciniak, W., Reszka, E., Białkowska, K., Jabłońska, E., Muszyńska, M., Lesicka, M., Derkacz, R., et al. (2020) · Biological Trace Element Research · doi:10.1007/s12011-020-02240-6 · Cited by 36
The link between chronic obstructive pulmonary disease phenotypes and histological subtypes of lung cancer: a case–control study
Wang, W., Xie, M., Dou, S., et al. (2018) · International Journal of COPD · doi:10.2147/copd.s158818 · Cited by 34
Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
Morcos, P. N., Nueesch, E., Jaminion, F., Guerini, E., Hsu, J., Bordogna, W., Balas, B. I., & Mercier, F. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3597-5 · Cited by 34
Asthma and asthma symptom control in relation to incidence of lung cancer in the HUNT study
Jiang, L., Sun, Y., Langhammer, A., Brumpton, B. M., Chen, Y., Nilsen, T. I., Leivseth, L., Wahl, S. G. F., & Mai, X. (2021) · Scientific Reports · doi:10.1038/s41598-021-84012-3 · Cited by 34
Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study)
Kreuter, M., Vansteenkiste, J., Fischer, J. R., Eberhardt, W., Zabeck, H., Kollmeier, J., Serke, M. H., Frickhofen, N., Reck, M., Engel-Riedel, W., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.09.014 · Cited by 33
Elevated Platelet Count Appears to Be Causally Associated with Increased Risk of Lung Cancer: A Mendelian Randomization Analysis
Zhu, Y., Wei, Y., Zhang, R., Dong, X., Shen, S., Zhao, Y., Bai, J., Albanes, D., Caporaso, N. E., Landi, M. T., et al. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-0356 · Cited by 33
Cannabis Use, Pulmonary Function, and Lung Cancer Susceptibility: A Mendelian Randomization Study
Baumeister, S., Baurecht, H., Nolde, M., Alayash, Z., Gläser, S., Johansson, M., Amos, C. I., Johnson, E. C., & Hung, R. J. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.025 · Cited by 32
Genetically predicted insomnia and lung cancer risk: a Mendelian randomization study
Huo, Z., Ge, F., Li, C., Cheng, H., Lu, Y., Wang, R., Wen, Y., Yue, K., Pan, Z., Peng, H., et al. (2021) · Sleep Medicine · doi:10.1016/j.sleep.2021.06.044 · Cited by 32
Self-citation
A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)
Zhou, Q. H., Song, Y., Zhang, X., Chen, G., Zhong, D., Yu, Z., Yu, P., Zhang, Y.-P., Chen, J., Hu, Y., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3451-x · Cited by 30
Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma
Li, Y., Xu, H., Su, S., Ye, J., Chen, J., Jin, X., Lin, Q. D., Zhang, D., Ye, C., & Chen, C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183331 · Cited by 30
Comparison of genetic profiles among primary lung tumor, metastatic lymph nodes and circulating tumor DNA in treatment-naïve advanced non-squamous non-small cell lung cancer patients
Xie, F., Zhang, Y., Mao, X., Zheng, X., Han‐Zhang, H., Ye, J., Zhao, R., Zhang, X., & Sun, J. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.05.002 · Cited by 30
Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial
Chu, T., Lü, J., Bi, M., Zhang, H., Zhuang, W., Yu, Y., Shi, J., Chen, Z., Zhang, X., Guo, Q., et al. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0212 · Cited by 30
The Invasiveness Classification of Ground-Glass Nodules Using 3D Attention Network and HRCT
Ni, Y., Yang, Y., Zheng, D., Xie, Z., Huang, H., & Wang, W. (2020) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-020-00355-9 · Cited by 27
Multiclassifier fusion based on radiomics features for the prediction of benign and malignant primary pulmonary solid nodules
Shen, Y., Xu, F., Zhu, W., Hu, H., Chen, T., & Li, Q. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.01.135 · Cited by 26
Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non–Small-Cell Lung Cancer
Ciuleanu, T., Socinski, M. A., Obasaju, C. K., Luft, A. V., Szczęsna, A., Szafrański, W., Ramlau, R., Bálint, B., Molinier, O., Depenbrock, H., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.10.004 · Cited by 24
Chronic Obstructive Pulmonary Disease in Lung Cancer Patients: Prevalence, Underdiagnosis, and Clinical Characterization
Mouronte‐Roibás, C., Leiro‐Fernández, V., Ruano‐Raviña, A., Hernández, C. R., Arca, J. A., Parente-Lamelas, I., Botana‐Rial, M., Priegue-Carrera, A., & Fernández‐Villar, A. (2018) · Respiration · doi:10.1159/000487243 · Cited by 24
The Prevalence and Concurrent Pathogenic Mutations of KRASG12C in Northeast Chinese Non-small-cell Lung Cancer Patients
Liu, Y., Li, H., Zhu, J., Zhang, Y., Liu, X., Li, R., Zhang, Q., & Cheng, Y. (2021) · Cancer Management and Research · doi:10.2147/cmar.s282617 · Cited by 23
Self-citation
Systematic analyses of genetic variants in chromatin interaction regions identified four novel lung cancer susceptibility loci
Ji, P., Ding, D.-S., Qin, N., Wang, C., Zhu, M., Li, Y., Dai, J., Jin, G., Hu, Z., Shen, H., et al. (2019) · Journal of Cancer · doi:10.7150/jca.35127 · Cited by 22
Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study
Lin, X., Peng, M., Chen, Q., Yuan, M., Chen, R., Deng, H., Deng, J., Liu, O., Weng, Y., Chen, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.774156 · Cited by 22
Self-citation
Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution
Li, D., Ding, L., Ran, W., Huang, Y., Li, G., Wang, C., Xiao, Y., Wang, X., Lin, D., & Xing, X. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13577 · Cited by 21
Molecular profiling of lung cancer specimens and liquid biopsies using MALDI-TOF mass spectrometry
Bonaparte, E., Pesenti, C., Fontana, L., Falcone, R., Paganini, L., Marzorati, A., Ferrero, S., Nosotti, M., Mendogni, P., Bareggi, C., et al. (2018) · Diagnostic Pathology · doi:10.1186/s13000-017-0683-7 · Cited by 20
BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
Caparica, R., de Castro, G., Bazo, I. G., Caglevic, C., Calogero, R., Giallombardo, M., Santos, E. S., Raez, L. E., & Rolfo, C. D. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.02.012 · Cited by 16
Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study
Wu, Y.-L. L. C., Zhou, C., Lü, S., Qin, S., Pan, H., Wu, G., Cheng, Y., Liu, X., Han, B., Zhu, Y., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.016 · Cited by 16
Self-citation
GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/ unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy
Zhou, Q. H., Chen, M., Wu, G., Chang, J., Jiang, O., Cui, J., Han, G., Lin, Q., Fang, J., Chen, G., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-608 · Cited by 16
The relationship between the severity of pulmonary fibrosis and the lung cancer stage
Jang, H. J., Park, M. S., Kim, Y. S., Chang, J., Lee, J. H., Lee, C., Lee, S. H., & Yoon, H. I. (2021) · Journal of Cancer · doi:10.7150/jca.51445 · Cited by 16
Subclassification of Non-Small Cell Lung Cancer by Cytologic Sampling: A Logical Approach with Selective Use of Immunocytochemistry
Kimbrell, H. Z., Gustafson, K. S., Huang, M., & Ehya, H. (2012) · Acta Cytologica · doi:10.1159/000338519 · Cited by 15
Trends in Molecular Testing of Lung Cancer in Mainland People’s Republic of China Over the Decade 2010 to 2019
Li, W., Lyu, Y., Wang, S., Zhou, X., Ma, J., Xu, C., Li, F., Ying, J., Guo, L., Qiu, T., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100163 · Cited by 12
Self-citation
MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
Wang, J., Wang, Z., Wu, L., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.181 · Cited by 11
The changing diagnostic pathway for lung cancer patients in Shanghai, China
Jiang, T., Ren, S., Li, X., Su, C., Zhou, C., & O'Brien, M. E. R. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.036 · Cited by 10
Self-citation
Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy
Zheng, Y., Lai, Q., Zhao, H., Li, X., Sun, X., & Xing, L. (2021) · 癌症：英文版 · doi:10.1002/cac2.12227 · Cited by 9
Validation of the diagnostic efficiency of folate receptor-positive circulating tumor cells in lung cancers: a prospective observational study
Liu, J., Han, M. K., & Huang, H. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.07.10 · Cited by 8
Excess Body Weight and Long-Term Incidence of Lung and Colon Cancer in Men; Follow-Up Study of 43 Years
Gepner, Y., Lev‐Ari, S., & Goldbourt, U. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph181910418 · Cited by 6
Polymorphisms and rare variants identified by next-generation sequencing confer risk for lung cancer in han Chinese population
Li, X., Liu, J., Wang, K., Zhou, J., Zhang, H., Zhang, M., & Shi, Y. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.152873 · Cited by 4

Emerging role of exosomes in cancer therapy: progress and challenges
Li, J., Wang, J., & Chen, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02215-4 · Cited by 297
Hypoxia-induced circ_0017521 enhances glycolysis and promotes NSCLC progression via upregulating the PFKFB3/PI3K-AKT pathway
Zhu, J., Yan, J., Zhang, Y., Zhu, X., & Chen, G. (2026) · Mammalian Genome · doi:10.1007/s00335-026-10202-x · Cited by 3

See all 656

Authors: Chen, P., Liu, Y., Wen, Y., & Zhou, C.
Venue: Cancer Communications
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2022-09-08
Volume: 42
Issue: 10
Pages: 937-970
ISSN: 1000-467X (ISSN-L)
2523-3548
DOI: 10.1002/cac2.12359
OpenAlex: W4295079305
Cited by: 656
References: 260
FWCI: 76.67
Type: journal article
Language: en
Open access: gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

Non‐small cell lung cancer in China

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources